ACSL3 and pancreatic ductal adenocarcinoma: Studies found that ACSL3 is upregulated in human pancreatic ductal adenocarcinoma (PDAC), and the deletion of ACSL3 could delay PDAC progression and reduce fibrosis in mice (56).